Therapy: Immunotherapy for T1DM-Targeting innate immunity

Nature Reviews Endocrinology

Volumn 9, Issue 7, 2013, Pages 384-385

  Wong, F Susan ^a   Wen, Li ^b  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; CRYOPYRIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN;

APOPTOSIS; CELL FUNCTION; CELLULAR STRESS RESPONSE; CYTOKINE RELEASE; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNOTHERAPY; INNATE IMMUNITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SHORT SURVEY;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1;

EID: 84879411763     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2013.103     Document Type: Short Survey

References (10)

1. Harjutsalo, V., Sjöberg, L. & Tuomilehto, J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 371, 1777-1782 (2008).
2. Moran, A. et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet http://dx.doi.org/10.1016/S0140-6736(13)60023-9.
3. Maedler, K. et al. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110, 851-860 (2002).
4. Kim, S. et al. Apoptosis of human islet cells by cytokines. Immune Netw. 12, 113-117 (2012).
5. Mills, K. H., Dungan, L. S., Jones, S. A. & Harris, J. The role of inflammasome-derived IL-1 in driving IL-17 responses. J. Leukoc. Biol. 93, 489-497 (2013).
6. Pipeleers, D. et al. Role of pancreatic β-cells in the process of β-cell death. Diabetes 50 (Suppl. 1), S52-S57 (2001).
7. Mandrup-Poulsen, T., Pickersgill, L. & Donath, M. Y. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat. Rev. Endocrinol. 6, 158-166 (2010).
8. Dinarello, C. A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117, 3720-3732 (2011).
9. + T lymphocytes requires Fas expression and is independent of IL-1 and IL-18. Eur. J. Immunol. 41, 1344-1351 (2011).
10. Ablamunits, V. et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 61, 145-154 (2012).